Ultragenyx Pharmaceutical Inc.
RARE
$35.11
-$0.87-2.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -151.08M | -133.39M | -133.52M | -131.60M | -170.68M |
| Total Depreciation and Amortization | 8.99M | 9.08M | 8.76M | 8.86M | 8.85M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 32.25M | 22.05M | 26.94M | 29.42M | 27.13M |
| Change in Net Operating Assets | -56.63M | 22.75M | 30.83M | 16.36M | -56.02M |
| Cash from Operations | -166.48M | -79.50M | -67.00M | -76.96M | -190.73M |
| Capital Expenditure | -1.32M | -654.00K | -1.62M | -2.01M | -3.21M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 121.21M | 103.39M | -273.89M | 62.57M | 97.65M |
| Cash from Investing | 119.89M | 102.74M | -275.50M | 60.56M | 94.44M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 157.00K | 3.19M | 4.17M | 384.88M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 7.00M | 58.00K | -58.00K |
| Cash from Financing | 157.00K | 3.19M | 11.17M | 384.94M | -58.00K |
| Foreign Exchange rate Adjustments | 1.45M | -2.47M | 1.28M | -648.00K | -679.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -44.98M | 23.95M | -330.05M | 367.89M | -97.03M |